Back to News
Market Impact: 0.25
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Lexicon Pharmaceuticals completed enrollment in its Phase III SONATA-HCM trial evaluating sotagliflozin for hypertrophic cardiomyopathy. Topline trial data are expected in Q1 2027, marking a clinical-development milestone but leaving a lengthy timeline to a potential regulatory catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
LXRX0.45
More News
- Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals
- Porsche could face another 4,000 job cuts, Handelsblatt reports
- Why is Telix Pharmaceuticals stock sliding today?
- Anthropic Mulls New AI Model Amid Investors' Pre-IPO Worries
- Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
- Williams-Sonoma's stock has soared in a sluggish housing market. Here's how it won over Wall Street